Literature DB >> 23121867

Addiction therapeutics: obstacles and opportunities.

Phil Skolnick1, Nora D Volkow.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23121867      PMCID： PMC4828659          DOI： 10.1016/j.biopsych.2012.08.004

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  8 in total

1.  New medications for substance use disorders: challenges and opportunities.

Authors:  Nora D Volkow; Phil Skolnick
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

2.  Reanalysis of methamphetamine dependence treatment trial.

Authors:  Celia Winchell; Bob A Rappaport; Rigoberto Roca; Curtis J Rosebraugh
Journal:  CNS Neurosci Ther       Date:  2012-05       Impact factor: 5.243

Review 3.  Interception of cocaine by enzyme or antibody delivered with viral gene transfer: a novel strategy for preventing relapse in recovering drug users.

Authors:  Stephen Brimijoin
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-12       Impact factor: 4.388

4.  Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials.

Authors:  Dennis M Donovan; George E Bigelow; Gregory S Brigham; Kathleen M Carroll; Allan J Cohen; John G Gardin; John A Hamilton; Marilyn A Huestis; John R Hughes; Robert Lindblad; G Alan Marlatt; Kenzie L Preston; Jeffrey A Selzer; Eugene C Somoza; Paul G Wakim; Elizabeth A Wells
Journal:  Addiction       Date:  2011-07-22       Impact factor: 6.526

Review 5.  Neurocircuitry of addiction.

Authors:  George F Koob; Nora D Volkow
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

6.  Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial.

Authors:  Bridget A Martell; Frank M Orson; James Poling; Ellen Mitchell; Roger D Rossen; Tracie Gardner; Thomas R Kosten
Journal:  Arch Gen Psychiatry       Date:  2009-10

7.  Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial.

Authors:  John J Mariani; Martina Pavlicova; Adam Bisaga; Edward V Nunes; Daniel J Brooks; Frances R Levin
Journal:  Biol Psychiatry       Date:  2012-07-12       Impact factor: 13.382

8.  Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic.

Authors:  D K Hatsukami; D E Jorenby; D Gonzales; N A Rigotti; E D Glover; C A Oncken; D P Tashkin; V I Reus; R C Akhavain; R E F Fahim; P D Kessler; M Niknian; M W Kalnik; S I Rennard
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875
  8 in total
  11 in total

Review 1.  Cocaine self-administration causes signaling deficits in corticostriatal circuitry that are reversed by BDNF in early withdrawal.

Authors:  Jacqueline F McGinty; Agnieska Zelek-Molik; Wei-Lun Sun
Journal:  Brain Res       Date:  2014-09-28       Impact factor: 3.252

2.  The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse.

Authors:  Megan Laudenbach; Federico Baruffaldi; Jeffrey S Vervacke; Mark D Distefano; Philip J Titcombe; Daniel L Mueller; Noah J Tubo; Thomas S Griffith; Marco Pravetoni
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

3.  G Protein and β-arrestin signaling bias at the ghrelin receptor.

Authors:  Tama Evron; Sean M Peterson; Nikhil M Urs; Yushi Bai; Lauren K Rochelle; Marc G Caron; Larry S Barak
Journal:  J Biol Chem       Date:  2014-09-26       Impact factor: 5.157

Review 4.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

5.  A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder.

Authors:  Andrea L Dimet; Irma E Cisneros; Robert G Fox; Sonja J Stutz; Noelle C Anastasio; Kathryn A Cunningham; Kelly T Dineley
Journal:  J Vis Exp       Date:  2018-06-18       Impact factor: 1.355

Review 6.  Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder.

Authors:  Leonard L Howell; Kathryn A Cunningham
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

7.  Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse.

Authors:  J J Taylor; M Laudenbach; A M Tucker; M K Jenkins; M Pravetoni
Journal:  J Immunol Methods       Date:  2014-01-23       Impact factor: 2.303

8.  Can Substance Use Disorders be Managed Using the Chronic Care Model? Review and Recommendations from a NIDA Consensus Group.

Authors:  A Thomas McLellan; Joanna L Starrels; Betty Tai; Adam J Gordon; Richard Brown; Udi Ghitza; Marc Gourevitch; Jack Stein; Marla Oros; Terry Horton; Robert Lindblad; Jennifer McNeely
Journal:  Public Health Rev       Date:  2014-01

Review 9.  Biomarkers for the development of new medications for cocaine dependence.

Authors:  Kristopher J Bough; Shashi Amur; Guifang Lao; Scott E Hemby; Nilesh S Tannu; Kyle M Kampman; Joy M Schmitz; Diana Martinez; Kalpana M Merchant; Charles Green; Jyoti Sharma; Anne H Dougherty; F Gerard Moeller
Journal:  Neuropsychopharmacology       Date:  2013-08-27       Impact factor: 7.853

10.  Safety and Preliminary Efficacy of Lorcaserin for Cocaine Use Disorder: A Phase I Randomized Clinical Trial.

Authors:  Sade E Johns; Lori Keyser-Marcus; Antonio Abbate; Edward Boone; Benjamin Van Tassell; Kathryn A Cunningham; Noelle C Anastasio; Justin L Poklis; Tatiana Ramey; F Gerard Moeller
Journal:  Front Psychiatry       Date:  2021-07-02       Impact factor: 4.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.